Company news

Vera Therapeutics, Inc. news in 2026

Vera Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 6, 2026

Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

November 5, 2026

Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

November 2, 2026

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine

October 22, 2026

Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast

October 20, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

October 2, 2026

Vera Therapeutics Announces TRUTAKNA Stabilized eGFR and Prevented Kidney Disease Progression through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

September 16, 2026

Vera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy

September 15, 2026

Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

August 10, 2026

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

July 9, 2026

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

July 7, 2026

VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026

June 10, 2026

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

June 2, 2026

Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026

Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

May 4, 2026

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

March 24, 2026

Vera Therapeutics Appoints Christopher Hite to Board of Directors

March 4, 2026

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

February 26, 2026

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

January 28, 2026

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 9, 2026

Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

January 7, 2026

Calls in 2026

Decks in 2026